Phase 3 Open-Label Study Evaluating the Efficacy and Safety of Mavacamten in Japanese Adults With Obstructive Hypertrophic Cardiomyopathy ― The HORIZON-HCM Study ―
Hiroaki Kitaoka(University of Kochi), Chisato Izumi(National Cerebral and Cardiovascular Center), Nobuyuki Komiyama(St. Luke's International Hospital), Hidetaka Miyagoshi(Bristol-Myers Squibb (Japan)), Tetsuya Watanabe(Osaka Prefectural Medical Center), Mio Ebato(Showa University Fujigaoka Hospital), Satoshi Yasuda(Tohoku University), Yasushi Sakata(The University of Osaka), Morimasa Takayama(Japanese Society of Medical Oncology), Akiyoshi Ogimoto(Uwajima City Hospital), Gen Kinoshita(Bristol-Myers Squibb (Japan)), Daigo Hiraya(University of Tsukuba), Sheila M. Hegde(Brigham and Women's Hospital), Tomofumi Takaya(Himeji Medical Center), Yuichiro Minami(Tokyo Women's Medical University), Ken Kozuma(Teikyo University Hospital), Yuichiro Maekawa(Hamamatsu University School of Medicine), Alison M. Reedy(Bristol-Myers Squibb (Germany)), Yutaka Furukawa(Kobe City Medical Center General Hospital), Victoria Florea(Fauna and Flora International), Eisuke Amiya(The University of Tokyo), Kaoru Tanno(SHOWA Medical University), Masaki Ieda(University of Tsukuba)
Cited by 23
Related Papers
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2020|1.2k
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|588
JCS 2020 Guideline Focused Update on Antithrombotic Therapy in Patients With Coronary Artery Disease
|Circulation Journal|2020|345